老年结直肠癌患者的治疗方法和生存结果:单中心比较研究
Beliz Bahar Karaoğlan1,2, Erman Akkuş3,4, Mehmet Kayaalp3,4
1Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Türkiye. bbaharulas@gmail.com.
概括
结直肠癌 (CRC) 的老年患者接受的化疗更少,生存率也更低,但年龄本身并不是CRC生存的独立预测因素. 虚弱影响老年人治疗的交付.
科学领域:
- 在瘤学瘤学.
- 老年医学 老年医学
- 临床研究 临床研究
背景情况:
- 大肠直肠癌 (CRC) 在老年患者中越来越多地被诊断出,这代表了重大的临床挑战.
- 了解老年人群中CRC的独特方面对于优化治疗和结果至关重要.
研究的目的:
- 为了比较临床病理特征,治疗方法,生存结果,以及老年人 (≥70岁) 与年轻人 (<70岁) CRC 患者的虚弱影响.
- 确定影响不同年龄组治疗决策和治疗结果的因素.
主要方法:
- 对2015年1月至2024年4月期间诊断的非转移性和新转移性CRC患者的回顾性分析.
- 老年人和年轻患者队列之间的人口统计,病理,治疗和生存数据的比较.
- 使用SPSS进行的统计分析,显著性设置为P < 0.05.
主要成果:
- 老年患者接受了较少的术后化疗 (60% vs. 81.6%) 并经历了更多的剂量减少 (41.6% vs. 19.2%).
- 脆弱性显著减少了老年非转移性患者的化疗,但没有影响剂量减少或治疗持续时间.
- 虽然老年患者在非转移组的整体生存率 (OS) 较低,但年龄在转移队列中没有独立影响OS或无进展生存率 (PFS). 早期终止化疗与更糟糕的生存状况有关.
结论:
- 年龄不是CRC存活的独立预后因素,但治疗差异和早期停止化疗会对结果产生负面影响.
- 降低剂量化疗或单疗等策略可以减轻副作用,并改善老年CRC患者的治疗坚持.
相关概念视频
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
01:20Comparing the Survival Analysis of Two or More Groups
155
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
155
01:24Kaplan-Meier Approach
102
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
102
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:20Actuarial Approach
63
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
63
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K